Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma
Authors:
- Feras Y. Al-RawashdehFAFeras Y. Al-Rawashdeh
- Peter ScrivenPSPeter Scriven
- Ian C. CameronICIan C. Cameron
- Patricia V. VerganiPVPatricia V. Vergani
- Lynda WyldLWLynda Wyld
- 1 September 2010
- journal article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 22 (9) , 1099-1105
Abstract
Hepatocellular carcinoma (HCC) has an annual worldwide incidence of 626 000 cases and causes 550 000 deaths per year. Although the mainstay of treatment is surgical resection, for inoperable or metastatic disease, chemotherapy may be offered. The primary agent used is doxorubicin, but response rates are poor (<20%). The unfolded protein response (UPR) is a cytoprotective cellular stress response that enables cells to survive periods of hypoxia and nutrient deprivation. The UPR may confer resistance to anticancer agents and contribute to treatment failure. This study has investigated whether the UPR is activated in HCC and whether this may contribute to doxorubicin resistance. Eighty-six human HCCs were immunohistochemically stained for glucose regulated protein 78, the key marker of UPR activation. An in-vitro model of UPR activation in HepG2 HCC cells was developed by glucose deprived culture. UPR activation was confirmed with western blotting and PCR to show overexpression of glucose regulated protein 78. The relative efficacy of doxorubicin chemotherapy on UPR-activated HepG2 cells was compared with normal HepG2 cells by use of an thiazolyl blue tetrazolium bromide colorimetric assay. Expression of glucose regulated protein 78 was shown in 100% of the HCC samples with 66% showing strong staining. In-vitro UPR activation was achieved with glucose deprivation. UPR activation induced significant resistance to doxorubicin: 34% survival under standard culture conditions versus 58% and 63% for UPR-activated cells in 0.5 and 1 mmol glucose respectively (P=0.00928). The UPR is activated in HCCs and confers resistance to chemotherapy in vitro. UPR activation may contribute to HCC chemoresistance.Keywords
This publication has 42 references indexed in Scilit:
- Systemic therapy of hepatocellular carcinoma: Are we making progress?Advances in Therapy, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Predicting survival in patients with hepatocellular carcinoma: A UK perspectiveEuropean Journal of Surgical Oncology, 2007
- Initial Response To Percutaneous Ablation Predicts Survival in Patients With Hepatocellular CarcinomaHepatology, 2004
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinomaEuropean Journal of Gastroenterology & Hepatology, 2000
- Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantationHepatology, 1999
- Characterization of the Nucleotide Binding Properties and ATPase Activity of Recombinant Hamster BiP Purified from BacteriaJournal of Biological Chemistry, 1995
- Blood flow and metabolic microenvironment of brain tumorsJournal of Neuro-Oncology, 1994
- The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteinsNature, 1988